First Trust Strategic Income ETF
Most Recent
Novartis’s Q2 2018 Earnings: Sandoz
Sandoz, the generics arm of Novartis (NVS), reported nearly flat revenues at ~$2.46 billion during Q2 2018.
Most Recent
Sandoz, the generics arm of Novartis (NVS), reported nearly flat revenues at ~$2.46 billion during Q2 2018.
